江苏硕世生物科技股份有限公司 2024 年年度股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2024 年年度股东大会会议材料 2025 年 5 月 28 日 江苏硕世生物科技股份有限公司 2024 年年度股东大会会议材料 江苏硕世生物科技股份有限公司 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世 生物科技股份有限公司股东大会议事规则》等相关规定，特制定 2024 年年度股 东大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-011 江苏硕世生物科技股份有限公司 关于公司控股股东股权结构变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次变动属于江苏硕世生物科技股份有限公司（以下简称"公司"）控股 股东绍兴闰康生物医药股权投资合伙企业（有限合伙）（以下简称"闰康生物"） 股权结构变动，未导致其所持有的公司股份数量及持股比例发生变化，不会对公 司经营产生重大影响，不触及要约收购。 本次股权结构拟变更前后，闰康生物的股权结构如下表： 单位：万元 | | 变更前 | | 变更后 | | | --- | --- | --- | --- | --- | | 股东名称 | 认缴出资额 | 占比 | 认缴出资额 | 占比 | 1 | 梁锡林 | 4,500.0000 | 71.8846% | 4,500.0000 | 71.8846% | | --- | --- | --- | --- | --- | | 房永生 | 500.0000 | 7.9872% | ...

重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 28 日 13 点 30 分 证券代码：688399 证券简称：硕世生物 公告编号：2025-012 江苏硕世生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年5月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投 ...

Core Viewpoint - The company reported a steady recovery in its business operations during the first quarter of 2025, with a year-on-year revenue growth of 0.54% and a quarter-on-quarter growth of 12.37% despite external pressures [3]. Financial Performance - The company achieved operating revenue of 0.92 billion yuan in the first quarter of 2025, reflecting a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37% [3]. - The overseas market showed significant growth, with overseas revenue increasing by 69.00% year-on-year due to prior product certifications and strategic deployment [3]. - The net profit declined due to price pressures from centralized procurement in the in vitro diagnostics industry, a VAT adjustment on self-produced testing reagents to 13%, and a reduction in government subsidies [3]. Asset Impairment - The company conducted impairment testing on its assets as of March 31, 2025, and recognized a total impairment provision of 59.06 thousand yuan, which included 18.64 thousand yuan for expected credit losses and 40.42 thousand yuan for inventory write-downs [13][14]. - The impairment provisions are expected to increase the company's profit before tax by 318.29 thousand yuan for the first quarter of 2025 [14]. Governance and Compliance - The board of directors and the supervisory board confirmed the accuracy and completeness of the quarterly report, ensuring compliance with relevant laws and regulations [2][8]. - The supervisory board reviewed and approved the first quarter report, affirming that it reflects the company's financial status and operational results accurately [8][9].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688399 证券简称：硕世生物 公告编号：2025-009 （3）监事会保证公司 2025 年第一季度报告所披露的信息真实、准确、完 整，公司在编制 2025 年第一季度报告的过程中，未发现参与 2025 年第一季度 报告编制和审议的人员有违反保密规定的行为。 江苏硕世生物科技股份有限公司 第三届监事会第九次会议决议公告 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 14:00 以现场结合通讯方式召开第三届监事会第九次会议（以下简称"本次 会议"）。本次会议通知于 2025 年 4 月 24 日向各位监事发出，本次会议应到 监事 3 人，实到监事 3 人。本次会议的召集、召开程序均符合《公司法》《证 券法》等法律、法规和规范性文件以及《公司章程》的规定。 会议由监事会主席马施达先生主持，经与会监事充分讨论，会议以记名投 票方式审议通过了如下议案： 一、审议通过《关于公司〈2025 年第一季度报告〉的议案》； 监事会在全面审阅公 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 91,608,367.51, a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37%[5]. - Net profit attributable to shareholders decreased by 68.01% to CNY 12,819,431.90 compared to the same period last year[5]. - Total operating revenue for Q1 2025 was CNY 91,608,367.51, a slight increase of 0.54% compared to CNY 91,119,399.55 in Q1 2024[21]. - Net profit for Q1 2025 decreased to CNY 12,819,431.90, down 68.0% from CNY 40,067,958.01 in Q1 2024[22]. - Earnings per share for Q1 2025 was CNY 0.23, compared to CNY 0.68 in Q1 2024, reflecting a decline of 66.2%[23]. Cash Flow - The net cash flow from operating activities dropped by 91.92% to CNY 4,267,255.23, primarily due to reduced sales receipts and government subsidies[5][11]. - Cash flow from operating activities for Q1 2025 was CNY 4,267,255.23, a decrease of 91.9% from CNY 52,790,211.13 in Q1 2024[27]. - Cash inflow from investment activities was CNY 1,285,826,932.20, significantly higher than CNY 704,037,566.52 in Q1 2024[27]. - Cash outflow from investment activities surged to CNY 1,906,180,377.20, compared to CNY 383,193,683.36 in the previous year, indicating increased investment activity[27]. - Cash flow from financing activities increased to CNY 267,900,000.00 in Q1 2025, up from CNY 193,148,017.81 in Q1 2024[27]. Assets and Liabilities - Total assets increased by 3.46% to CNY 3,869,325,179.71 compared to the end of the previous year[6]. - The company's current assets decreased slightly to CNY 2,133,253,327.45 from CNY 2,139,295,851.19, indicating a reduction of about 0.28%[17]. - Total liabilities rose to CNY 605,873,720.44 from CNY 489,315,989.30, marking an increase of approximately 23.9%[18]. - The company's non-current assets increased to CNY 1,736,071,852.26 from CNY 1,600,652,165.48, reflecting a growth of about 8.5%[17]. - The total equity remained stable at CNY 3,263,451,459.27, unchanged from the previous reporting period[18]. Research and Development - Research and development expenses totaled CNY 19,092,486.00, accounting for 20.84% of revenue, a decrease of 0.85 percentage points from the previous year[6]. - The company reported a significant increase in research and development expenses, totaling CNY 19,092,486.00 for Q1 2025, compared to CNY 19,762,499.26 in Q1 2024[21]. Market and Pricing - Overseas revenue grew significantly by 69.00% due to prior product certifications and strategic deployment in international markets[7]. - The company faced pressure on product pricing due to the deep implementation of centralized procurement in the in vitro diagnostics industry[7]. - Government subsidies decreased year-on-year, contributing to the decline in net profit[7]. Other Financial Metrics - The basic earnings per share decreased by 66.18% to CNY 0.23, reflecting the decline in net profit[6][11]. - The weighted average return on equity fell by 0.78 percentage points to 0.39%[6]. - Cash and cash equivalents saw a significant decline, dropping to CNY 329,915,492.31 from CNY 810,632,720.07, a decrease of approximately 59.3%[16]. - The accounts receivable increased slightly to CNY 55,178,822.98 from CNY 53,822,041.97, showing a growth of about 2.5%[16]. - Inventory decreased to CNY 59,168,414.06 from CNY 67,044,790.50, indicating a decline of approximately 11.7%[17].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 4 月 29 日，江苏硕世生物科技股份有限公司（以下简称"公司" 或者"硕世生物"）第三届董事会第十一次会议、第三届监事会第九次会议审 议通过了《关于 2025 年第一季度计提及转回资产减值准备的议案》，该议案无 需提交公司股东大会审议，现将具体事宜公告如下： 一、本次计提资产减值准备情况概述 证券代码：688399 证券简称：硕世生物 公告编号：2025-010 江苏硕世生物科技股份有限公司 关于 2025 年第一季度计提及转回资产减值准备 的公告 根据《企业会计准则》的规定，公司对合并报表范围内截至 2025 年 3 月 31 日的各类资产进行了减值测试，对存在减值迹象的资产计提了减值准备。经 测试，公司 2025 年第一季度计提减值准备具体情况如下表： 单位：人民币万元 | | 项目 | 2025 年第一季度 计提减值准备金额 | | 2025 年第一季度 计入减值损失金额 | | --- | --- | --- | --- | --- | | 信用减值 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 72.55 CNY [5][13]. Core Views - The company's performance has significantly improved, and the release of new products is expected to drive growth [2]. - The impact of centralized procurement on the company is still being digested, leading to a downward adjustment in revenue and gross margin forecasts for in vitro diagnostic reagents, medical instruments, and testing services [5]. - The company is projected to achieve a net profit attributable to shareholders of 0.20 billion CNY, 0.23 billion CNY, and 0.27 billion CNY for the years 2025-2027, respectively [5]. Financial Summary - In 2023, the company reported a revenue of 403 million CNY, which is expected to decline to 350 million CNY in 2024, before recovering to 410 million CNY in 2025, and reaching 570 million CNY by 2027 [7][15]. - The gross margin for 2024 is projected at 62.3%, with a gradual increase to 70.4% by 2027 [7][15]. - The net profit margin is expected to turn positive by 2025, with a forecasted net profit of 20 million CNY, increasing to 27 million CNY by 2027 [7][15]. - The company has improved its cash flow, achieving a positive operating cash flow of 1.46 billion CNY in 2024, a significant increase of 229% year-on-year [13]. Product Performance - In 2024, the revenue from diagnostic reagents is expected to be 314 million CNY, with a year-on-year decline of 10.8%, while the sales of nucleic acid purification reagents and molecular diagnostic reagents are projected to grow by 30.1% and 5.5%, respectively [13]. - The revenue from diagnostic instruments is anticipated to be 13 million CNY, down 9.8% year-on-year, and testing services are expected to decline by 64.2% to 5 million CNY [13]. Research and Development - The company has obtained 9 new domestic medical device product registration certificates and 18 filings in 2024, launching several new diagnostic products [13]. - The focus remains on enhancing research capabilities and expanding into six major areas, including reproductive health and infectious disease prevention [13].

Group 1 - The company achieved an operating revenue of 621 million yuan in 2024, representing a year-on-year growth of 24.9% [1] - The net profit attributable to shareholders was a loss of 12.58 million yuan, which is a reduction compared to the previous year's loss [1] - Research and development investment reached 73.09 million yuan, accounting for 11.76% of operating revenue, an increase of 1.59 percentage points from 2023 [1] Group 2 - In the electronic chemicals business, the company's main revenue grew by over 30% year-on-year, achieving large-scale applications in several high-end fields [2] - The company successfully expanded its overseas market in general electroplating chemicals, particularly achieving large-scale application of high-speed tin plating products in Belarus [2] - The company has made progress in the "chemicals + equipment" collaborative development model, enhancing its competitiveness in the market [2]

证券代码：688399 证券简称：硕世生物 公告编号：2025-003 江苏硕世生物科技股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日 14:00 以现场方式召开第三届监事会第八次会议（以下简称"本次会议"）。 本次会议通知于 2025 年 4 月 7 日向各位监事发出，本次会议应到监事 3 人，实 到监事 3 人。本次会议的召集、召开程序均符合《公司法》《证券法》等法律、 法规和规范性文件以及《公司章程》的规定。 会议由监事会主席马施达先生主持，经与会监事充分讨论，会议以记名投 票方式审议通过了如下议案： 一、审议通过《关于〈2024 年度监事会工作报告〉的议案》； 监事会认为：2024 年，监事会根据《公司法》《证券法》《公司章程》 《监事会议事规则》等规定，认真履行各项职权和义务，在维护公司利益、股 东合法权益、改善公司法人治理结构、建立健全公司管理制度等工作中恪尽职 守，加强对公司财务状 ...